Alvotech (ICE: ALVO)
Iceland
· Delayed Price · Currency is ISK
1,645.00
-10.00 (-0.60%)
At close: Dec 20, 2024
Alvotech Employees
Alvotech had 999 employees as of December 31, 2023. The number of employees increased by 82 or 8.94% compared to the previous year.
Employees
999
Change (1Y)
82
Growth (1Y)
8.94%
Revenue / Employee
53.20M ISK
Profits / Employee
-59.62M ISK
Market Cap
500.33B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 999 | 82 | 8.94% |
Dec 31, 2022 | 917 | 133 | 16.96% |
Dec 31, 2021 | 784 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Oculis Holding AG | 36 |
Marel hf. | 7,500 |
Íslandsbanki hf. | 764 |
Arion banki hf. | 822 |
Sildarvinnslan Hf. | 723 |
Brim hf. | 694 |
Hagar hf | 2,699 |
Kvika banki hf. | 270 |
Alvotech News
- 4 weeks ago - Alvotech's Position In The Coming Biosimilar Gold Rush - Seeking Alpha
- 5 weeks ago - Alvotech (ALVO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - GlobeNewsWire
- 6 weeks ago - European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - GlobeNewsWire
- 2 months ago - Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - GlobeNewsWire
- 2 months ago - Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - GlobeNewsWire
- 2 months ago - Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - GlobeNewsWire
- 2 months ago - Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - GlobeNewsWire